Mayoux, Eric
Boehringer Ingelheim (Germany)
3 papers on CoChat
Most cited papers
- Verified
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care
Diabetes Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 975
- Verified
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 483
- Verified
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism
Chronic Kidney Disease and DiabetesAcute Kidney Injury Research
Cited by 376
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free